This report tracks 24 key events expected in September, 3Q and 2H including TG Therapeutics’ ublituximab in chronic lymphocytic leukemia, Vital Therapies’ ELAD in alcoholic hepatitis and Zealand Pharma’s dasiglucagon in severe hypoglycemia.
A sampling of headlines:
• TG’s UNITY-CLL study of ublituximab/umbralisib has strong success chances with low-bar comparator, but combo faces strong competition
• Vital’s ELAD machine for alcoholic hepatitis draws mixed expert reviews even if specific patients enrolled; severe protocols major uptake hurdle
• Zealand Pharma’s dasiglucagon has high T1D Phase III success prospects with earlier data; market domination expected over Eli Lilly’s Glucagon and Novo Nordisk’s GlucaGen if approved